Evidence map›Paper›PMID 34873015›Full record

ArticleNeurology2022

Dermatomyositis: Muscle Pathology According to Antibody Subtypes.

Jantima Tanboon, Michio Inoue, Yoshihiko Saito, Hisateru Tachimori, Shinichiro Hayashi, Satoru Noguchi, Naoko Okiyama, Manabu Fujimoto, Ichizo Nishino

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 78 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Myopathies in clinical care: a focus on treatable causes.Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Review
  9. Myopathies in clinical care: a focus on treatable causes.Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 2 countries.

Jantima TanboonFrom the Department of Neuromuscular Research, National Institute of Neuroscience (J.T., M.I., Y.S., S.H., S.N., I.N.), Department of Genome Medicine Development, Medical Genome Center (J.T., M.I., Y.S., S.H., S.N., I.N.), and Department of Clinical Epidemiology, Translational Medical Center (H.T.), National Center of Neurology and Psychiatry (NCNP); Endowed Course for Health System Innovation (H.T.), Keio University School of Medicine, Tokyo; Department of Dermatology, Faculty of Medicine (N.O.), University of Tsukuba, Ibaraki; and Department of Dermatology (M.F.), Graduate School of Medicine, Osaka University, Japan.
Michio InoueFrom the Department of Neuromuscular Research, National Institute of Neuroscience (J.T., M.I., Y.S., S.H., S.N., I.N.), Department of Genome Medicine Development, Medical Genome Center (J.T., M.I., Y.S., S.H., S.N., I.N.), and Department of Clinical Epidemiology, Translational Medical Center (H.T.), National Center of Neurology and Psychiatry (NCNP); Endowed Course for Health System Innovation (H.T.), Keio University School of Medicine, Tokyo; Department of Dermatology, Faculty of Medicine (N.O.), University of Tsukuba, Ibaraki; and Department of Dermatology (M.F.), Graduate School of Medicine, Osaka University, Japan.ORCID 0000-0003-2757-3266
Yoshihiko SaitoFrom the Department of Neuromuscular Research, National Institute of Neuroscience (J.T., M.I., Y.S., S.H., S.N., I.N.), Department of Genome Medicine Development, Medical Genome Center (J.T., M.I., Y.S., S.H., S.N., I.N.), and Department of Clinical Epidemiology, Translational Medical Center (H.T.), National Center of Neurology and Psychiatry (NCNP); Endowed Course for Health System Innovation (H.T.), Keio University School of Medicine, Tokyo; Department of Dermatology, Faculty of Medicine (N.O.), University of Tsukuba, Ibaraki; and Department of Dermatology (M.F.), Graduate School of Medicine, Osaka University, Japan.
Hisateru TachimoriFrom the Department of Neuromuscular Research, National Institute of Neuroscience (J.T., M.I., Y.S., S.H., S.N., I.N.), Department of Genome Medicine Development, Medical Genome Center (J.T., M.I., Y.S., S.H., S.N., I.N.), and Department of Clinical Epidemiology, Translational Medical Center (H.T.), National Center of Neurology and Psychiatry (NCNP); Endowed Course for Health System Innovation (H.T.), Keio University School of Medicine, Tokyo; Department of Dermatology, Faculty of Medicine (N.O.), University of Tsukuba, Ibaraki; and Department of Dermatology (M.F.), Graduate School of Medicine, Osaka University, Japan.
Shinichiro HayashiFrom the Department of Neuromuscular Research, National Institute of Neuroscience (J.T., M.I., Y.S., S.H., S.N., I.N.), Department of Genome Medicine Development, Medical Genome Center (J.T., M.I., Y.S., S.H., S.N., I.N.), and Department of Clinical Epidemiology, Translational Medical Center (H.T.), National Center of Neurology and Psychiatry (NCNP); Endowed Course for Health System Innovation (H.T.), Keio University School of Medicine, Tokyo; Department of Dermatology, Faculty of Medicine (N.O.), University of Tsukuba, Ibaraki; and Department of Dermatology (M.F.), Graduate School of Medicine, Osaka University, Japan.
Satoru NoguchiFrom the Department of Neuromuscular Research, National Institute of Neuroscience (J.T., M.I., Y.S., S.H., S.N., I.N.), Department of Genome Medicine Development, Medical Genome Center (J.T., M.I., Y.S., S.H., S.N., I.N.), and Department of Clinical Epidemiology, Translational Medical Center (H.T.), National Center of Neurology and Psychiatry (NCNP); Endowed Course for Health System Innovation (H.T.), Keio University School of Medicine, Tokyo; Department of Dermatology, Faculty of Medicine (N.O.), University of Tsukuba, Ibaraki; and Department of Dermatology (M.F.), Graduate School of Medicine, Osaka University, Japan.ORCID 0000-0001-6165-3716
Naoko OkiyamaFrom the Department of Neuromuscular Research, National Institute of Neuroscience (J.T., M.I., Y.S., S.H., S.N., I.N.), Department of Genome Medicine Development, Medical Genome Center (J.T., M.I., Y.S., S.H., S.N., I.N.), and Department of Clinical Epidemiology, Translational Medical Center (H.T.), National Center of Neurology and Psychiatry (NCNP); Endowed Course for Health System Innovation (H.T.), Keio University School of Medicine, Tokyo; Department of Dermatology, Faculty of Medicine (N.O.), University of Tsukuba, Ibaraki; and Department of Dermatology (M.F.), Graduate School of Medicine, Osaka University, Japan.ORCID 0000-0002-5398-0773
Manabu FujimotoFrom the Department of Neuromuscular Research, National Institute of Neuroscience (J.T., M.I., Y.S., S.H., S.N., I.N.), Department of Genome Medicine Development, Medical Genome Center (J.T., M.I., Y.S., S.H., S.N., I.N.), and Department of Clinical Epidemiology, Translational Medical Center (H.T.), National Center of Neurology and Psychiatry (NCNP); Endowed Course for Health System Innovation (H.T.), Keio University School of Medicine, Tokyo; Department of Dermatology, Faculty of Medicine (N.O.), University of Tsukuba, Ibaraki; and Department of Dermatology (M.F.), Graduate School of Medicine, Osaka University, Japan.
Ichizo NishinoFrom the Department of Neuromuscular Research, National Institute of Neuroscience (J.T., M.I., Y.S., S.H., S.N., I.N.), Department of Genome Medicine Development, Medical Genome Center (J.T., M.I., Y.S., S.H., S.N., I.N.), and Department of Clinical Epidemiology, Translational Medical Center (H.T.), National Center of Neurology and Psychiatry (NCNP); Endowed Course for Health System Innovation (H.T.), Keio University School of Medicine, Tokyo; Department of Dermatology, Faculty of Medicine (N.O.), University of Tsukuba, Ibaraki; and Department of Dermatology (M.F.), Graduate School of Medicine, Osaka University, Japan. nishino@ncnp.go.jp.
University of Tsukuba · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesDiscoveries of dermatomyositis-specific antibodies (DMSAs) in patients with dermatomyositis raised awareness of various myopathologic features among antibody subtypes. However, only perifascicular atrophy and perifascicular myxovirus resistant protein A (MxA) overexpression were officially included as definitive pathologic criteria for dermatomyositis classification. We aimed to demonstrate myopathologic features in MxA-positive dermatomyositis to determine characteristic myopathologic features in different DMSA subtypes.

methodsWe performed a retrospective pathology review of muscle biopsies of patients with dermatomyositis diagnosed between January 2009 and December 2020 in a tertiary laboratory for muscle diseases. We included all muscle biopsies with sarcoplasmic expression for MxA and seropositivity for DMSAs. MxA-positive muscle biopsies that tested negative for all DMSAs were included as seronegative dermatomyositis. We evaluated histologic features stratified according to 4 pathology domains (muscle fiber, inflammatory, vascular, and connective tissue) and histologic features of interest by histochemistry, enzyme histochemistry, and immunohistochemical study commonly used in the diagnosis of inflammatory myopathy. We performed ultrastructural studies of 54 available specimens.

resultsA total of 256 patients were included. Of these, 249 patients were positive for 1 of the 5 DMSAs (seropositive patients: 87 anti-transcription intermediary factor 1-γ [TIF1-γ], 40 anti-complex nucleosome remodeling histone deacetylase [Mi-2], 29 anti-melanoma differentiation gene 5 [MDA5], 83 anti-nuclear matrix protein 2 [NXP-2], and 10 anti-small ubiquitin-like modifier-activating enzyme [SAE] dermatomyositis) and 7 patients were negative for all 5 DMSAs (seronegative patients). Characteristic myopathologic features in each DMSA subtype were as follows: anti-TIF1-γ with vacuolated/punched out fibers (64.7%; DISCUSSION: We describe a comprehensive serologic-pathologic correlation of dermatomyositis primarily using MxA expression as an inclusion criterion. In our study, DMSAs were associated with distinctive myopathologic features suggesting different underlying pathobiologic mechanisms in each subtype.

Indexed as

DermatomyositisMuscular DiseasesMyositisAutoantibodiesHumansMuscle Fibers, SkeletalRetrospective StudiesAutoantibodies

Identifiers

PMID34873015
PMCPMC8865893
OpenAlexW4212919282

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.